LABU241004C124000
- 5.16
- +0.25+5.09%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Dr. Reddy's Signs Voluntary Licensing Agreement With Gilead Sciences To Manufacture And Commercialise Lenacapavir In India And Other Countries
Morgan Stanley Identifies 39 Stocks Likely to Face Tax Loss Selling Pressure
Gilead Signs Deals With Six Drugmakers for Generic Lenacapavir
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
Capital Markets' Top 30 Global Ideas for the Fourth Quarter
CVS, Cigna PBMs Targeted as Lawmakers Criticize New "Anti-competitive" Move
AbbVie Withdraws Exviera From EU Market for Commercial Reasons
Incyte Analyst Ratings
Optimism Around Aquestive As It Moves Forward With Severe Allergy, Baldness Candidate
'Buy This; Sell That' Within Each Sector – Oppenheimer
Meta, Accenture, Disney And A Major Health Care Stock On CNBC's 'Final Trades'
Reported Earlier, Alnylam's Vutrisiran Data Highlights Early Impact on Key Cardiac Biomarkers, Alnylam Eyes First-Line Therapy for ATTR Amyloidosis
Stocks With the Highest Consensus of Expected ROE Growth, Goldman Sachs Says
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
(ABBV) - Analyzing AbbVie's Short Interest
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Exact Sciences, Quanterix Extend Slide After Medicare Rates
Raymond James Reiterates Market Perform on Exact Sciences